Triple positive (ER+PR+/HER-2+) breast carcinomas occur at a younger age than all other ER/PR/HER-2 breast cancer phenotypes

被引：0
|
作者：
Neven, P. [1 ,2 ]
Bempt, I. Vanden [3 ]
Van Calster, B. [4 ]
Hendrickx, W. [5 ]
De Cock, J. [5 ]
Cheng, J. [4 ]
Timmerman, D. [2 ]
Paridaens, R. [1 ,6 ]
Christiaens, M. R. [1 ,7 ]
Drijkoningen, M. [1 ,3 ]
机构：
[1] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium
[2] UZ Leuven, Dept Obstet & Gynecol, Leuven, Belgium
[3] UZ Leuven, Dept Histopathol, Leuven, Belgium
[4] Katholieke Univ Leuven, ESAT KU Leuven, Leuven, Belgium
[5] UZ Leuven, Datamanagement MBC, Leuven, Belgium
[6] UZ Leuven, Dept Med Oncol, Leuven, Belgium
[7] UZ Leuven, Dept Surg, Leuven, Belgium
来源：
BREAST | 2007年 / 16卷
关键词：
D O I：
10.1016/S0960-9776(07)70119-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [21] Immunohistochemical Staining of HER-2, VEGF, ER and PR in Breast Tissues from Sudanese Patients
    Abdeladi, Hala Ahmed
    Mohammed, Mohammed Elimam Ahamed
    Eltayeb, Mohammed Ahmed
    INTERNATIONAL JOURNAL OF MEDICAL RESEARCH & HEALTH SCIENCES, 2018, 7 (08): : 46 - 53
  • [22] MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer
    Radojicic, Jelena
    Zaravinos, Apostolos
    Vrekoussis, Thomas
    Kafousi, Maria
    Spandidos, Demetrios A.
    Stathopoulos, Efstathios N.
    CELL CYCLE, 2011, 10 (03) : 507 - 517
  • [23] EFFECTS OF RESVERATROL ON TRIPLE NEGATIVE (ER-, PR-, HER2-) BREAST CANCER CELLS
    Mangum, Carla
    Cameron, Joseph A.
    Herbert, Brittney-Shea
    FASEB JOURNAL, 2008, 22
  • [24] Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer
    Sutela, Anna
    Vanninen, Ritva
    Sudah, Mazen
    Berg, Marja
    Kiviniemi, Vesa
    Rummukainen, Jaana
    Kataja, Vesa
    Karja, Vesa
    ACTA ONCOLOGICA, 2008, 47 (01) : 38 - 46
  • [25] Clinicopathological differences and survival benefit in ER+/PR+/HER2+vs ER+/PR-/HER2+breast cancer subtypes
    Ding, Wu
    Ye, Dengfeng
    Chen, Haifeng
    Lin, Yingli
    Li, Zhian
    Tu, Chuanjian
    BREAST CANCER, 2024, 31 (02) : 295 - 304
  • [26] Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer
    Hayashi, Naoki
    Iwamoto, Takayuki
    Gonzalez-Angulo, Ana M.
    Ferrer-Lozano, Jaime
    Lluch, Ana
    Niikura, Naoki
    Bartholomeusz, Chandra
    Nakamura, Seigo
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    ONCOLOGIST, 2011, 16 (07): : 956 - 965
  • [27] Prognostic significance of ER-to-PR difference in ER+/HER2-early breast cancer
    Wu, Xiaoyan
    Zhang, Wenchuan
    Lu, Xunxi
    Zhong, Xiaorong
    Bu, Hong
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [28] Relationship of ER, PR, HER2 / neu with Other Prognostic Factors in Breast Cancer along with the Role of Androgen Receptor in Triple Negative Breast Cancer
    Khan, Arshi
    Malik, Reeni
    Jain, Pramila
    Verma, Deepshikha
    Newasker, Vedanti
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2021, 10 (08): : 536 - 540
  • [29] Effect of Trastuzumab on Locoregional Recurrence in HER2-Positive Breast Cancer According to ER/PR Status
    Kim, M. M.
    Dawood, S.
    Allen, P.
    Sahin, A.
    Woodward, W.
    Strom, E. A.
    Hunt, K. K.
    Meric-Bernstam, F.
    Gonzalez-Angulo, A.
    Buchholz, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S35 - S35
  • [30] Alternations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications
    Caigang Liu
    Hao Zhang
    Chen Shuang
    Yang Lu
    Feng Jin
    Huimian Xu
    Ping Lu
    Medical Oncology, 2010, 27 : 747 - 752
12345